본문으로 건너뛰기
← 뒤로

Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib.

1/5 보강
Cancers 📖 저널 OA 100% 2021: 20/20 OA 2022: 79/79 OA 2023: 89/89 OA 2024: 156/156 OA 2025: 683/683 OA 2026: 512/512 OA 2021~2026 2026 Vol.18(6)
Retraction 확인
출처

Han K, Jwa EK, Ha S, Kim J, Lee R, Lee E, Kang S, Kim HO, Kwon H, Jung DH, Yoon YI, Song GW, Park GC, Kim TW, Namgoon JM, Hwang S, Tak E, Lee SG

📝 환자 설명용 한 줄

[BACKGROUND] Sorafenib resistance remains a major barrier to effective therapy in hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC).

이 논문을 인용하기

↓ .bib ↓ .ris
APA Han K, Jwa EK, et al. (2026). Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib.. Cancers, 18(6). https://doi.org/10.3390/cancers18061038
MLA Han K, et al.. "Therapeutic Targeting of miR-21 Restores SASH1 and Sensitizes HBV-HCC to Sorafenib.." Cancers, vol. 18, no. 6, 2026.
PMID 41899638 ↗

Abstract

[BACKGROUND] Sorafenib resistance remains a major barrier to effective therapy in hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC).

[INTRODUCTION] Here, we identified a previously undefined mechanism by which miR-21 promotes sorafenib resistance by suppressing the tumor suppressor SASH1 and enhancing HBx-driven PI3K/AKT/mTOR signaling.

[METHODS] miR-21 expression was markedly elevated in HBV-HCC tissues, HBV-integrated HCC cell lines, and hypoxic conditions. Bioinformatic analyses and luciferase reporter assays confirmed SASH1 as a direct miR-21 target.

[RESULTS] Mechanistically, SASH1 was functionally associated with HBx-related oncogenic signaling and influenced apoptotic responses. miR-21 inhibition reduced HBV-HCC cell proliferation, increased apoptosis, and restored sorafenib sensitivity in vitro. In an orthotopic HBV-HCC mouse model, the combined administration of miR-21 inhibitor and sorafenib elicited markedly greater tumor suppression and restoration of the SASH1 expression than either monotherapy did.

[DISCUSSION] Therefore, these findings suggested that the miR-21/SASH1 pathway contributed to therapeutic resistance in HBV-associated HCC and highlighted that miR-21 targeting could be an efficient strategy to improve sorafenib response.

[CONCLUSIONS] The miR-21/SASH1 axis play a critical role in sorafenib resistance in HBV-associated HCC, and targeting miR-21 may provide a promising therapeutic strategy to enhance treatment efficacy.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (5)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기